Outcomes in unresectable and locally advanced resected cholangiocarcinoma

Expert Review of Anticancer Therapy

Volumn 11, Issue 5, 2011, Pages 705-709

  Payne, Sarah Jl ^a   Stebbing, Justin ^b   Wilson, Peter ^a   Slater, Sarah ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

biliary tract; cancer; cisplatin; gemcitabine; radiotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHOTON THERAPY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE;

EID: 79955837406     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.32     Document Type: Article

References (28)

1. Leong E, Chen WW, Ng E, Van Hazel G, Mitchell A, Spry N. Outcomes from combined chemoradiotherapy in unresectable and locally advanced resected cholangiocarcinoma. J. Gastrointest. Cancer DOI: 10.1007/s12029-010-9213-5 (2010) (Epub ahead of print).
2. Verslype C, Prenen H, Van Cutsem E. The role of chemotherapy in biliary tract carcinoma. HPB (Oxford) 10(3), 164-167 (2008).
3. Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg. Today 35(7), 548-552 (2005).
4. Stein DE, Heron DE, Rosato EL, Anne PR, Topham AK. Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy. Am. J. Clin. Oncol. 28(1), 21-23 (2005).
5. Itoh H, Nishijima K, Kurosaka Y et al. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig. Dis. Sci. 50(12), 2231-2242 (2005).
6. Hughes MA, Frassica DA, Yeo CJ et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int. J. Radiat. Oncol. Biol. Phys. 68(1), 178-182 (2007).
7. Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and defnitive treatment of intrahepatic cholangiocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 72(5), 1495-1501 (2008).
8. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J. Gastroenterol. 15(34), 4240-4262 (2009).
9. Ishii H, Furuse J, Nagase M, Kawashima M, Ikeda H, Yoshino M. Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting. Hepatogastroenterology 51(58), 954-957 (2004).
10. 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 57(5), 1357-1365 (2003).
11. Golferi R, Giampalma E, Fusco F et al. Unresectable hilar cholangiocarcinoma: multimodality treatment with percutaneous and intraluminal plus external radiotherapy. J. Chemother. 16(Suppl. 5), 55-57 (2004).
12. Kuvshinoff BW, Armstrong JG, Fong Y et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br. J. Surg. 82(11), 1522-1525 (1995).
13. Morganti AG, Trodella L, Valentini V et al. Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 46(4), 913-919 (2000).
14. Nelson J W, Ghafoori AP, Willett CG et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 73(1), 148-153 (2009).
15. Kim S, Kim SW, Bang YJ et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int. J. Radiat. Oncol. Biol. Phys. 54(2), 414-419 (2002).
16. Ben-David MA, Griffth KA, Abu-Isa E et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 66(3), 772-779 (2006).
17. Gerhards MF, van Gulik TM, González González D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J. Surg. 27(2), 173-179 (2003).
18. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273-1281 (2010).
19. Sharma A, Dwary AD, Mohanti BK et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J. Clin. Oncol. 28(30), 4581-4586 (2010).
20. Sharma A, Dwary AD, Mohanti BK et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J. Clin. Oncol. 28(30), 4581-4586 (2010).
21. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273-1281 (2010).
22. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br. J. Cancer 96(6), 896-902 (2007).
23. Gatto M, Alvaro D. New insights on cholangiocarcinoma. World J. Gastrointest. Oncol. 2(3), 136-145 (2010).
24. Friman S, Foss A, Isoniemi H et al. Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results. Scand. J. Gastroenterol. 46(3), 370-375 (2010).
25. Kim JH, Yoon HK, Kim SY et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol. Ther. 29(12), 1291-1298 (2009).
26. Zhu AX, Meyerhardt JA, Blaszkowsky LS et al. Effcacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fuorodeoxyglucose PET with clinical outcome: a Phase 2 study. Lancet Oncol. 11(1), 48-54 (2010).
27. Gruenberger B, Schueller J, Heubrandtner U et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a Phase 2 study. Lancet Oncol. 11(12), 1142-1148 (2010).
28. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J. Clin. Oncol. 28(21), 3531-3540 (2010).